Tag: Cancer: Breast
Neoantigen DNA Vaccines Safe, Induce Response in Triple-Negative Breast Cancer
Fourteen of 18 patients had neoantigen-specific T-cell responses; recurrence-free survival was 87.5 percent at 36 months
Inavolisib + Palbociclib-Fulvestrant Improves Survival in Advanced Breast Cancer
Inavolisib leads to significantly longer progression-free survival, with no increase seen in incidence of toxic events
Multigene Signature Can Help Tailor Chemo for Operable Triple-Negative Breast Cancer
Improved three-year disease-free and recurrence-free survival seen with intensive chemotherapy regimen
Guideline-Concordant Care Less Likely With Non-Hispanic Black Race
Findings seen in older patients with breast cancer; non-Hispanic Black patients also less likely to have timely initiation of treatment
Medicaid Expansion Increases Guideline-Concordant Treatment for Breast Cancer
Increase seen in receipt of guideline-concordant treatment for women newly diagnosed with HR-negative, HER2-positive breast cancer
No Objective Improvement Seen in Cognitive Function With Exercise During Chemo
Significant differences seen in four of six self-reported cognitive function outcomes favoring aerobic exercise initiated with chemo
Breast Cancer Risk Elevated With Levonorgestrel-Releasing Intrauterine System Use
Excess risk of 14 per 10,000 women seen with zero to five years of LNG-IUS use
Excess Adiposity Plays Role in Postmenopausal HR-Positive Breast Cancer
Estimated burden of 19.9 percent reported for body mass index and 41.9 percent for Clínica Universidad de Navarra-Body Adiposity Estimator
FDA Approves Itovebi for Locally Advanced, Metastatic Breast Cancer
Approval is for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative disease
Increasing Amount of Breast Cancer-Specific Death Due to Stage 1, 2 Disease
Authors say strategies are needed to identify early-stage breast cancer survivors at risk for recurrence
